- Home
- SBRA vs CYTK Comparison
SBRA vs CYTK Comparison
Compare SBRA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- CYTK
- Stock Information
- Founded
- SBRA 2010
- CYTK 1997
- Country
- SBRA United States
- CYTK United States
- Employees
- SBRA N/A
- CYTK N/A
- Industry
- SBRA Real Estate Investment Trusts
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- SBRA Real Estate
- CYTK Health Care
- Exchange
- SBRA Nasdaq
- CYTK Nasdaq
- Market Cap
- SBRA 4.3B
- CYTK 4.6B
- IPO Year
- SBRA N/A
- CYTK 2004
- Fundamental
- Price
- SBRA $18.00
- CYTK $59.46
- Analyst Decision
- SBRA Hold
- CYTK Strong Buy
- Analyst Count
- SBRA 8
- CYTK 15
- Target Price
- SBRA $20.50
- CYTK $76.73
- AVG Volume (30 Days)
- SBRA 2.9M
- CYTK 1.7M
- Earning Date
- SBRA 11-05-2025
- CYTK 11-05-2025
- Dividend Yield
- SBRA 6.67%
- CYTK N/A
- EPS Growth
- SBRA 236.12
- CYTK N/A
- EPS
- SBRA 0.76
- CYTK N/A
- Revenue
- SBRA $734,008,000.00
- CYTK $85,738,000.00
- Revenue This Year
- SBRA $7.42
- CYTK $363.61
- Revenue Next Year
- SBRA $8.86
- CYTK $64.08
- P/E Ratio
- SBRA $23.67
- CYTK N/A
- Revenue Growth
- SBRA 10.21
- CYTK 2635.74
- 52 Week Low
- SBRA $15.60
- CYTK $29.31
- 52 Week High
- SBRA $20.03
- CYTK $64.13
- Technical
- Relative Strength Index (RSI)
- SBRA 46.62
- CYTK 53.67
- Support Level
- SBRA $17.17
- CYTK $54.30
- Resistance Level
- SBRA $18.70
- CYTK $64.13
- Average True Range (ATR)
- SBRA 0.44
- CYTK 2.74
- MACD
- SBRA 0.01
- CYTK -0.34
- Stochastic Oscillator
- SBRA 43.89
- CYTK 51.53
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.